Avidity Biosciences, Inc. (RNA) 10-Year Financial Performance & Capital Metrics

RNA •

HealthcareBiotechnologyRNA and Genome Editing Developers

AboutAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Show more

Revenue $19M +72.1%
EBITDA -$742M -97.2%
Net Income -$685M -112.4%
EPS (Diluted) -4.97 -72.0%
Gross Margin 77.87% -22.1%
EBITDA Margin -3955.17% -14.6%
Operating Margin -3977.3% -14.4%
Net Margin -3650.39% -23.4%
ROE -43.98% -31.4%
ROIC -42.83% -15.8%
Debt/Equity 0.06 +1073.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 22.5%
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 23.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y22.54%

3Y26.69%

TTM72.11%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-112.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-71.38%

ROCE

10Y Avg-36.67%

5Y Avg-38.92%

3Y Avg-41.79%

Latest-46.21%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	379K	2.32M	6.79M	9.33M	9.22M	9.56M	10.9M	18.75M
Revenue Growth %	-	511.87%	192.67%	37.41%	-1.09%	3.64%	13.99%	72.11%
Cost of Goods Sold+	8.44M	0	37.6M	101.18M	1.39M	2.1M	0	4.15M
COGS % of Revenue	2225.86%	-	554.03%	1084.95%	15.04%	21.98%	-	22.13%
Gross Profit+	-8.06M	2.32M	-30.82M	-91.86M	7.84M	7.46M	10.9M	14.6M
Gross Margin %	-2125.86%	100%	-454.03%	-984.95%	84.96%	78.02%	100%	77.87%
Gross Profit Growth %	-	128.78%	-1428.81%	-198.09%	108.53%	-4.82%	46.09%	34.02%
Operating Expenses+	10.88M	19.65M	13.46M	26.2M	186.75M	243.06M	389.83M	760.55M
OpEx % of Revenue	2869.92%	847.39%	198.35%	280.88%	2024.61%	2542.44%	3577.43%	4055.17%
Selling, General & Admin	2.44M	5.11M	13.46M	26.2M	37.73M	54.19M	86.24M	205.54M
SG&A % of Revenue	644.06%	220.44%	198.35%	280.88%	409.07%	566.84%	791.41%	1095.92%
Research & Development	8.44M	14.54M	37.6M	101.18M	150.4M	190.97M	303.59M	559.16M
R&D % of Revenue	2225.86%	626.95%	554.03%	1084.95%	1630.57%	1997.57%	2786.02%	2981.39%
Other Operating Expenses	0	0	-37.6M	-101.18M	-1.39M	-2.1M	0	-4.15M
Operating Income+	-10.5M	-17.33M	-44.28M	-118.05M	-178.91M	-235.6M	-378.94M	-745.94M
Operating Margin %	-2769.92%	-747.39%	-652.38%	-1265.83%	-1939.65%	-2464.41%	-3477.43%	-3977.3%
Operating Income Growth %	-	-65.1%	-155.46%	-166.62%	-51.56%	-31.68%	-60.84%	-96.85%
EBITDA+	-10.12M	-16.98M	-43.9M	-117.41M	-177.53M	-233.5M	-376.16M	-741.79M
EBITDA Margin %	-2668.87%	-732.38%	-646.88%	-1258.97%	-1924.61%	-2442.44%	-3451.96%	-3955.17%
EBITDA Growth %	-	-67.91%	-158.5%	-167.43%	-51.2%	-31.53%	-61.1%	-97.2%
D&A (Non-Cash Add-back)	383K	348K	373K	639K	1.39M	2.1M	2.78M	4.15M
EBIT	-10.5M	-17.35M	-44.15M	-118.05M	-178.91M	-235.6M	-378.94M	-684.63M
Net Interest Income+	-718K	-7.39M	-3K	104K	4.97M	23.97M	56.88M	63.26M
Interest Income	0	0	206K	104K	4.97M	23.97M	56.88M	63.26M
Interest Expense	718K	7.39M	209K	0	0	0	0	0
Other Income/Expense	-718K	-7.4M	-78K	42K	4.92M	23.38M	56.63M	61.31M
Pretax Income+	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Pretax Margin %	-2959.37%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Income Tax+	718K	0	0	0	0	0	0	0
Effective Tax Rate %	106.4%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-11.93M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Net Margin %	-3148.81%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Net Income Growth %	-	-107.26%	-79.33%	-166.06%	-47.44%	-21.97%	-51.87%	-112.42%
Net Income (Continuing)	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.58	-0.86	-2.05	-2.85	-3.34	-2.91	-2.89	-4.97
EPS Growth %	-	-48.28%	-138.37%	-39.02%	-17.19%	12.87%	0.69%	-71.97%
EPS (Basic)	-0.58	-0.86	-2.05	-2.85	-3.34	-2.91	-2.89	-4.97
Diluted Shares Outstanding	20.68M	37.51M	21.66M	41.43M	52.16M	73.01M	111.58M	137.71M
Basic Shares Outstanding	20.68M	37.51M	21.66M	41.43M	52.16M	73.01M	111.58M	137.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	3.24M	95.68M	331.68M	411.14M	622.94M	611.31M	1.54B	1.8B
Cash & Short-Term Investments	3.09M	94.58M	328.14M	405.54M	610.73M	595.35M	1.5B	1.7B
Cash Only	3.09M	94.58M	321.46M	320.45M	340.4M	185.08M	219.87M	382.52M
Short-Term Investments	0	0	6.68M	85.09M	270.33M	410.27M	1.28B	1.31B
Accounts Receivable	0	0	1.2M	900K	3.88M	8.62M	28.22M	12.44M
Days Sales Outstanding	-	-	64.54	35.22	153.34	329.23	945.31	242.08
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	152K	0	0	0	0	0	0	89.16M
Total Non-Current Assets+	740K	1.23M	2.22M	16.44M	15.86M	17.25M	21.61M	159.58M
Property, Plant & Equipment	702K	631K	1.92M	15.59M	15.01M	16.65M	18.29M	74.61M
Fixed Asset Turnover	0.54x	3.68x	3.53x	0.60x	0.61x	0.57x	0.60x	0.25x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	38K	600K	298K	850K	849K	596K	3.32M	84.97M
Total Assets+	3.98M	96.91M	333.9M	427.58M	638.8M	628.55M	1.56B	1.96B
Asset Turnover	0.10x	0.02x	0.02x	0.02x	0.01x	0.02x	0.01x	0.01x
Asset Growth %	-	2333.63%	244.56%	28.06%	49.4%	-1.6%	148.81%	25.2%
Total Current Liabilities+	4.62M	10.24M	14.59M	29.66M	51.91M	80.68M	98.02M	195.45M
Accounts Payable	1.56M	2.31M	7.75M	2.81M	4.64M	8.81M	8.46M	12.4M
Days Payables Outstanding	67.71	-	75.18	10.12	1.22K	1.53K	-	1.09K
Short-Term Debt	2.75M	2.77M	0	0	0	0	0	3.94M
Deferred Revenue (Current)	0	3.84M	0	0	5.04M	28.36M	20.99M	21.64M
Other Current Liabilities	305K	0	3.69M	4.86M	11.19M	14.34M	3.66M	157.47M
Current Ratio	0.70x	9.35x	22.74x	13.86x	12.00x	7.58x	15.73x	9.20x
Quick Ratio	0.70x	9.35x	22.74x	13.86x	12.00x	7.58x	15.73x	9.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	40.49M	152.03M	13.09M	16.49M	8.82M	47.11M	40.92M	74M
Long-Term Debt	7.58M	1.77M	0	0	0	0	0	45.31M
Capital Lease Obligations	0	393K	938K	9.96M	7.58M	6.21M	2.96M	45.31M
Deferred Tax Liabilities	0	134.72M	0	0	0	0	0	0
Other Non-Current Liabilities	32.92M	45K	12.15M	6.53M	0	0	0	-45.31M
Total Liabilities	45.11M	162.26M	27.68M	46.15M	60.73M	127.79M	138.94M	269.45M
Total Debt+	10.32M	4.94M	938K	11.73M	10.69M	9.85M	6.8M	94.56M
Net Debt	7.23M	-89.64M	-320.52M	-308.72M	-329.71M	-175.23M	-213.07M	-287.95M
Debt / Equity	-	-	0.00x	0.03x	0.02x	0.02x	0.00x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-14.62x	-2.35x	-211.85x	-	-	-	-	-
Total Equity+	-41.13M	-65.36M	306.22M	381.43M	578.08M	500.76M	1.42B	1.69B
Equity Growth %	-	-58.91%	568.54%	24.56%	51.55%	-13.37%	184.56%	18.5%
Book Value per Share	-1.99	-1.74	14.14	9.21	11.08	6.86	12.77	12.26
Total Shareholders' Equity	-41.13M	-65.36M	306.22M	381.43M	578.08M	500.76M	1.42B	1.69B
Common Stock	426K	1K	4K	5K	7K	8K	12K	15K
Retained Earnings	-41.55M	-22.18M	-66.54M	-184.55M	-358.54M	-570.76M	-893.07M	-1.58B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-33.12M	-134.72M	-5K	-187K	-2.7M	125K	2.9M	2.56M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-9.65M	2.49M	-37.12M	-94.81M	-136.27M	-119.06M	-300.87M	-650.44M
Operating CF Margin %	-2547.49%	107.37%	-546.88%	-1016.65%	-1477.32%	-1245.44%	-2761.04%	-3468.09%
Operating CF Growth %	-	125.79%	-1590.64%	-155.44%	-43.72%	12.63%	-152.7%	-116.19%
Net Income	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Depreciation & Amortization	383K	348K	373K	639K	1.39M	2.1M	2.78M	-8.37M
Stock-Based Compensation	60K	406K	4.31M	17.06M	27.14M	38.22M	51.36M	97.84M
Deferred Taxes	0	0	84K	0	0	0	0	0
Other Non-Cash Items	447K	7.11M	139K	163K	-615K	-8.3M	-18.15M	4.38M
Working Capital Changes	671K	19.36M	2.33M	5.34M	9.82M	61.13M	-14.56M	-59.66M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	780K	436K	5.75M	6.04M	18.32M	1.77M	35.18M	3.8M
Cash from Investing+	-49K	-235K	-7.79M	-82.52M	-189.96M	-130.07M	-854.2M	-38.03M
Capital Expenditures	-49K	-235K	-1.09M	-3.74M	-2.82M	-4.23M	-7.07M	-13.32M
CapEx % of Revenue	12.93%	10.13%	16.09%	40.1%	30.6%	44.23%	64.84%	71.02%
Acquisitions	0	0	0	82.52M	187.13M	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-82.52M	-187.13M	0	0	-4.07M
Cash from Financing+	5.14M	89.23M	272.04M	176.32M	346.17M	93.86M	1.19B	850.99M
Debt Issued (Net)	4.98M	16.65M	-4.68M	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	-106K	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	162K	65K	466K	1.64M	1.39M	2.13M	191.81M	-12.41M
Net Change in Cash	-4.56M	91.49M	227.13M	-1.01M	19.95M	-155.27M	37.29M	162.65M
Free Cash Flow+	-9.7M	2.25M	-38.21M	-98.55M	-139.09M	-123.29M	-307.94M	-663.76M
FCF Margin %	-2560.42%	97.24%	-562.97%	-1056.76%	-1507.92%	-1289.67%	-2825.88%	-3539.11%
FCF Growth %	-	123.24%	-1794.41%	-157.93%	-41.13%	11.36%	-149.76%	-115.55%
FCF per Share	-0.47	0.06	-1.76	-2.38	-2.67	-1.69	-2.76	-4.82
FCF Conversion (FCF/Net Income)	0.81x	-0.10x	0.84x	0.80x	0.78x	0.56x	0.93x	0.95x
Interest Paid	0	322K	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-36.83%	-34.32%	-36.27%	-39.34%	-33.47%	-43.98%
Return on Invested Capital (ROIC)	-	-	-	-303.16%	-83.58%	-61.58%	-36.97%	-42.83%
Gross Margin	-2125.86%	100%	-454.03%	-984.95%	84.96%	78.02%	100%	77.87%
Net Margin	-3148.81%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Debt / Equity	-	-	0.00x	0.03x	0.02x	0.02x	0.00x	0.06x
Interest Coverage	-14.62x	-2.35x	-211.85x	-	-	-	-	-
FCF Conversion	0.81x	-0.10x	0.84x	0.80x	0.78x	0.56x	0.93x	0.95x
Revenue Growth	-	511.87%	192.67%	37.41%	-1.09%	3.64%	13.99%	72.11%

US Stock Screener

...

Avidity Biosciences, Inc. (RNA) 10-Year Financial Performance & Capital Metrics

RNA •

HealthcareBiotechnologyRNA and Genome Editing Developers

Revenue $19M +72.1%
EBITDA -$742M -97.2%
Net Income -$685M -112.4%
EPS (Diluted) -4.97 -72.0%
Gross Margin 77.87% -22.1%
EBITDA Margin -3955.17% -14.6%
Operating Margin -3977.3% -14.4%
Net Margin -3650.39% -23.4%
ROE -43.98% -31.4%
ROIC -42.83% -15.8%
Debt/Equity 0.06 +1073.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 22.5%
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 2 (bottom 2%)
✗Shares diluted 23.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y22.54%

3Y26.69%

TTM72.11%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-112.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-71.38%

ROCE

10Y Avg-36.67%

5Y Avg-38.92%

3Y Avg-41.79%

Latest-46.21%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	379K	2.32M	6.79M	9.33M	9.22M	9.56M	10.9M	18.75M
Revenue Growth %	-	511.87%	192.67%	37.41%	-1.09%	3.64%	13.99%	72.11%
Cost of Goods Sold+	8.44M	0	37.6M	101.18M	1.39M	2.1M	0	4.15M
COGS % of Revenue	2225.86%	-	554.03%	1084.95%	15.04%	21.98%	-	22.13%
Gross Profit+	-8.06M	2.32M	-30.82M	-91.86M	7.84M	7.46M	10.9M	14.6M
Gross Margin %	-2125.86%	100%	-454.03%	-984.95%	84.96%	78.02%	100%	77.87%
Gross Profit Growth %	-	128.78%	-1428.81%	-198.09%	108.53%	-4.82%	46.09%	34.02%
Operating Expenses+	10.88M	19.65M	13.46M	26.2M	186.75M	243.06M	389.83M	760.55M
OpEx % of Revenue	2869.92%	847.39%	198.35%	280.88%	2024.61%	2542.44%	3577.43%	4055.17%
Selling, General & Admin	2.44M	5.11M	13.46M	26.2M	37.73M	54.19M	86.24M	205.54M
SG&A % of Revenue	644.06%	220.44%	198.35%	280.88%	409.07%	566.84%	791.41%	1095.92%
Research & Development	8.44M	14.54M	37.6M	101.18M	150.4M	190.97M	303.59M	559.16M
R&D % of Revenue	2225.86%	626.95%	554.03%	1084.95%	1630.57%	1997.57%	2786.02%	2981.39%
Other Operating Expenses	0	0	-37.6M	-101.18M	-1.39M	-2.1M	0	-4.15M
Operating Income+	-10.5M	-17.33M	-44.28M	-118.05M	-178.91M	-235.6M	-378.94M	-745.94M
Operating Margin %	-2769.92%	-747.39%	-652.38%	-1265.83%	-1939.65%	-2464.41%	-3477.43%	-3977.3%
Operating Income Growth %	-	-65.1%	-155.46%	-166.62%	-51.56%	-31.68%	-60.84%	-96.85%
EBITDA+	-10.12M	-16.98M	-43.9M	-117.41M	-177.53M	-233.5M	-376.16M	-741.79M
EBITDA Margin %	-2668.87%	-732.38%	-646.88%	-1258.97%	-1924.61%	-2442.44%	-3451.96%	-3955.17%
EBITDA Growth %	-	-67.91%	-158.5%	-167.43%	-51.2%	-31.53%	-61.1%	-97.2%
D&A (Non-Cash Add-back)	383K	348K	373K	639K	1.39M	2.1M	2.78M	4.15M
EBIT	-10.5M	-17.35M	-44.15M	-118.05M	-178.91M	-235.6M	-378.94M	-684.63M
Net Interest Income+	-718K	-7.39M	-3K	104K	4.97M	23.97M	56.88M	63.26M
Interest Income	0	0	206K	104K	4.97M	23.97M	56.88M	63.26M
Interest Expense	718K	7.39M	209K	0	0	0	0	0
Other Income/Expense	-718K	-7.4M	-78K	42K	4.92M	23.38M	56.63M	61.31M
Pretax Income+	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Pretax Margin %	-2959.37%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Income Tax+	718K	0	0	0	0	0	0	0
Effective Tax Rate %	106.4%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-11.93M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Net Margin %	-3148.81%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Net Income Growth %	-	-107.26%	-79.33%	-166.06%	-47.44%	-21.97%	-51.87%	-112.42%
Net Income (Continuing)	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.58	-0.86	-2.05	-2.85	-3.34	-2.91	-2.89	-4.97
EPS Growth %	-	-48.28%	-138.37%	-39.02%	-17.19%	12.87%	0.69%	-71.97%
EPS (Basic)	-0.58	-0.86	-2.05	-2.85	-3.34	-2.91	-2.89	-4.97
Diluted Shares Outstanding	20.68M	37.51M	21.66M	41.43M	52.16M	73.01M	111.58M	137.71M
Basic Shares Outstanding	20.68M	37.51M	21.66M	41.43M	52.16M	73.01M	111.58M	137.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	3.24M	95.68M	331.68M	411.14M	622.94M	611.31M	1.54B	1.8B
Cash & Short-Term Investments	3.09M	94.58M	328.14M	405.54M	610.73M	595.35M	1.5B	1.7B
Cash Only	3.09M	94.58M	321.46M	320.45M	340.4M	185.08M	219.87M	382.52M
Short-Term Investments	0	0	6.68M	85.09M	270.33M	410.27M	1.28B	1.31B
Accounts Receivable	0	0	1.2M	900K	3.88M	8.62M	28.22M	12.44M
Days Sales Outstanding	-	-	64.54	35.22	153.34	329.23	945.31	242.08
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	152K	0	0	0	0	0	0	89.16M
Total Non-Current Assets+	740K	1.23M	2.22M	16.44M	15.86M	17.25M	21.61M	159.58M
Property, Plant & Equipment	702K	631K	1.92M	15.59M	15.01M	16.65M	18.29M	74.61M
Fixed Asset Turnover	0.54x	3.68x	3.53x	0.60x	0.61x	0.57x	0.60x	0.25x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0
Other Non-Current Assets	38K	600K	298K	850K	849K	596K	3.32M	84.97M
Total Assets+	3.98M	96.91M	333.9M	427.58M	638.8M	628.55M	1.56B	1.96B
Asset Turnover	0.10x	0.02x	0.02x	0.02x	0.01x	0.02x	0.01x	0.01x
Asset Growth %	-	2333.63%	244.56%	28.06%	49.4%	-1.6%	148.81%	25.2%
Total Current Liabilities+	4.62M	10.24M	14.59M	29.66M	51.91M	80.68M	98.02M	195.45M
Accounts Payable	1.56M	2.31M	7.75M	2.81M	4.64M	8.81M	8.46M	12.4M
Days Payables Outstanding	67.71	-	75.18	10.12	1.22K	1.53K	-	1.09K
Short-Term Debt	2.75M	2.77M	0	0	0	0	0	3.94M
Deferred Revenue (Current)	0	3.84M	0	0	5.04M	28.36M	20.99M	21.64M
Other Current Liabilities	305K	0	3.69M	4.86M	11.19M	14.34M	3.66M	157.47M
Current Ratio	0.70x	9.35x	22.74x	13.86x	12.00x	7.58x	15.73x	9.20x
Quick Ratio	0.70x	9.35x	22.74x	13.86x	12.00x	7.58x	15.73x	9.20x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	40.49M	152.03M	13.09M	16.49M	8.82M	47.11M	40.92M	74M
Long-Term Debt	7.58M	1.77M	0	0	0	0	0	45.31M
Capital Lease Obligations	0	393K	938K	9.96M	7.58M	6.21M	2.96M	45.31M
Deferred Tax Liabilities	0	134.72M	0	0	0	0	0	0
Other Non-Current Liabilities	32.92M	45K	12.15M	6.53M	0	0	0	-45.31M
Total Liabilities	45.11M	162.26M	27.68M	46.15M	60.73M	127.79M	138.94M	269.45M
Total Debt+	10.32M	4.94M	938K	11.73M	10.69M	9.85M	6.8M	94.56M
Net Debt	7.23M	-89.64M	-320.52M	-308.72M	-329.71M	-175.23M	-213.07M	-287.95M
Debt / Equity	-	-	0.00x	0.03x	0.02x	0.02x	0.00x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-14.62x	-2.35x	-211.85x	-	-	-	-	-
Total Equity+	-41.13M	-65.36M	306.22M	381.43M	578.08M	500.76M	1.42B	1.69B
Equity Growth %	-	-58.91%	568.54%	24.56%	51.55%	-13.37%	184.56%	18.5%
Book Value per Share	-1.99	-1.74	14.14	9.21	11.08	6.86	12.77	12.26
Total Shareholders' Equity	-41.13M	-65.36M	306.22M	381.43M	578.08M	500.76M	1.42B	1.69B
Common Stock	426K	1K	4K	5K	7K	8K	12K	15K
Retained Earnings	-41.55M	-22.18M	-66.54M	-184.55M	-358.54M	-570.76M	-893.07M	-1.58B
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-33.12M	-134.72M	-5K	-187K	-2.7M	125K	2.9M	2.56M
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-9.65M	2.49M	-37.12M	-94.81M	-136.27M	-119.06M	-300.87M	-650.44M
Operating CF Margin %	-2547.49%	107.37%	-546.88%	-1016.65%	-1477.32%	-1245.44%	-2761.04%	-3468.09%
Operating CF Growth %	-	125.79%	-1590.64%	-155.44%	-43.72%	12.63%	-152.7%	-116.19%
Net Income	-11.22M	-24.73M	-44.35M	-118.01M	-174M	-212.22M	-322.3M	-684.63M
Depreciation & Amortization	383K	348K	373K	639K	1.39M	2.1M	2.78M	-8.37M
Stock-Based Compensation	60K	406K	4.31M	17.06M	27.14M	38.22M	51.36M	97.84M
Deferred Taxes	0	0	84K	0	0	0	0	0
Other Non-Cash Items	447K	7.11M	139K	163K	-615K	-8.3M	-18.15M	4.38M
Working Capital Changes	671K	19.36M	2.33M	5.34M	9.82M	61.13M	-14.56M	-59.66M
Change in Receivables	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	780K	436K	5.75M	6.04M	18.32M	1.77M	35.18M	3.8M
Cash from Investing+	-49K	-235K	-7.79M	-82.52M	-189.96M	-130.07M	-854.2M	-38.03M
Capital Expenditures	-49K	-235K	-1.09M	-3.74M	-2.82M	-4.23M	-7.07M	-13.32M
CapEx % of Revenue	12.93%	10.13%	16.09%	40.1%	30.6%	44.23%	64.84%	71.02%
Acquisitions	0	0	0	82.52M	187.13M	0	0	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-82.52M	-187.13M	0	0	-4.07M
Cash from Financing+	5.14M	89.23M	272.04M	176.32M	346.17M	93.86M	1.19B	850.99M
Debt Issued (Net)	4.98M	16.65M	-4.68M	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	-106K	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0
Other Financing	162K	65K	466K	1.64M	1.39M	2.13M	191.81M	-12.41M
Net Change in Cash	-4.56M	91.49M	227.13M	-1.01M	19.95M	-155.27M	37.29M	162.65M
Free Cash Flow+	-9.7M	2.25M	-38.21M	-98.55M	-139.09M	-123.29M	-307.94M	-663.76M
FCF Margin %	-2560.42%	97.24%	-562.97%	-1056.76%	-1507.92%	-1289.67%	-2825.88%	-3539.11%
FCF Growth %	-	123.24%	-1794.41%	-157.93%	-41.13%	11.36%	-149.76%	-115.55%
FCF per Share	-0.47	0.06	-1.76	-2.38	-2.67	-1.69	-2.76	-4.82
FCF Conversion (FCF/Net Income)	0.81x	-0.10x	0.84x	0.80x	0.78x	0.56x	0.93x	0.95x
Interest Paid	0	322K	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-36.83%	-34.32%	-36.27%	-39.34%	-33.47%	-43.98%
Return on Invested Capital (ROIC)	-	-	-	-303.16%	-83.58%	-61.58%	-36.97%	-42.83%
Gross Margin	-2125.86%	100%	-454.03%	-984.95%	84.96%	78.02%	100%	77.87%
Net Margin	-3148.81%	-1066.58%	-653.53%	-1265.38%	-1886.33%	-2219.87%	-2957.71%	-3650.39%
Debt / Equity	-	-	0.00x	0.03x	0.02x	0.02x	0.00x	0.06x
Interest Coverage	-14.62x	-2.35x	-211.85x	-	-	-	-	-
FCF Conversion	0.81x	-0.10x	0.84x	0.80x	0.78x	0.56x	0.93x	0.95x
Revenue Growth	-	511.87%	192.67%	37.41%	-1.09%	3.64%	13.99%	72.11%

Avidity Biosciences, Inc. (RNA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RNA vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Avidity Biosciences, Inc. (RNA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RNA vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios